by Raynovich Rod | Apr 25, 2017 | 2025 Rayno Biopharmaceuticals Portfolio
Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for...
by Raynovich Rod | Apr 15, 2017 | Biopharmaceuticals
Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at...
by Raynovich Rod | Apr 11, 2017 | Biopharmaceuticals
Biotech Doldrums: Nothing to Entice Buyers Trump Agenda for Tax Reform and Deregulation Stalls Geopolitical News Curbs Market Sentiment Recent geopolitical news has created a backdrop that has discouraged investors in biotech who were already risk averse from drug...
by Raynovich Rod | Mar 21, 2017 | Biopharmaceuticals
3/22 Update after close..Relief Rally Awaiting Tomorrow’s Vote Large Caps-mostly green with IBB up 0.54%. Mid Caps-some strength RDUS up 3.48% SGEN up 1.74 %, ,TSRO up 4.08%. Small caps XBI up 0.98%. NASDAQ up 0.48%. ========== Biotech Stocks Sink on Trump...
by Raynovich Rod | Mar 17, 2017 | Biopharmaceuticals
Upbeat Drug Study Data from an Amgen Cholesterol Trial but Stocks are Clobbered Because of Higher Expectations LDL cholesterol is a Toxic Risk Factor Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of...
by Raynovich Rod | Feb 20, 2017 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79....
by Raynovich Rod | Feb 11, 2017 | Biopharmaceuticals
Top Biopharmaceutical Stocks : Performance and Financial Metrics after 2016 Earnings We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction...
by Raynovich Rod | Feb 10, 2017 | Biopharmaceuticals
Update-1… 1:45p EST Biotech Rally Biogen (BIIB) looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI slight gains. ======== Biotech Rally Takes Levels to January Top IBB up 1% to $284.56, up 7.2% YTD XBI up 1.79% to $67.07, up 13.3%...
by Raynovich Rod | Jan 13, 2017 | Biopharmaceuticals
Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference The market recovered slightly today from yesterday’s “Trump storm” attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat....
by Raynovich Rod | Jan 2, 2017 | Biopharmaceuticals
Update-2…1/6/17– Three Day Biotech Rally…12N EST NASDAQ at New Highs 5532 XBI is up 5 points since last Friday’s close to $63.45;The IBB is up 16 points to $280. Investors are betting on a turnaround in healthcare with positive news from the...
